Exhaustion

Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies
Daniela GM Tantalo, Amanda J Oliver, Bianca von Scheidt, Aaron J Harrison, Scott N Mueller, Michael H Kershaw, Clare Y Slaney

Journal for ImmunoTherapy of Cancer May 2021, 9 (5) e002555; DOI: 10.1136/jitc-2021-002555
Moving forward to address key unanswered questions on targeting PD-1/PD-L1 in cancer: limitations in preclinical models and the need to incorporate human modifying factors
Catherine T. Le, William J. Murphy

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 291; DOI: 10.1186/s40425-019-0789-4
Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy
Paola Dama, Marshall Tang, Noreen Fulton, Justin Kline, Hongtao Liu

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 175; DOI: 10.1186/s40425-019-0611-3
HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics
Andressa S. Laino, B. C. Betts, A. Veerapathran, I. Dolgalev, A. Sarnaik, S. N. Quayle, S. S. Jones, J. S. Weber, David M. Woods

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 33; DOI: 10.1186/s40425-019-0517-0
Combination immunotherapy: Where do we go from here?
Abigail E. Overacre, Sema Kurtulus, Mario Sznol, Drew M. Pardoll, Ana Anderson, Dario A. A. Vignali

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (1) 38; DOI: 10.1186/s40425-015-0083-z

Main menu